Strategic deals at GE and Oracle will support their wide moats, while AbbVie aims for tax relief in its bid for Shire.
The near-term outlook for GE is good, but investors should wait for a bigger margin of safety in the shares before jumping in, says Morningstar's Daniel Holland .
Many rapid prototyping firms have deteriorating business fundamentals and are trading at lofty valuations after a strong runup.
Five stats from the market and the stories behind them. This week: Berkshire's stake in a $28 billion deal, Avon's not-so-pretty 1% sales growth, and more.
China cools, Fannie and Freddie fall, and Amazon's wide moat backs a Prime decision.
Wear, tear, and competition will drive a comeback in this sector.
Market volatility has shaped the performance of many top managers this year.
Morningstar's industrials team looks beyond today to find value for the future.
Berkshire's portfolio can give some guidance to weary investors.